Mack Gene 4
4 · Gain Therapeutics, Inc. · Filed Mar 26, 2026
Research Summary
AI-generated summary of this filing
Gain Therapeutics CEO Mack Gene Receives 200,000-Share Award
What Happened
- Mack Gene, CEO, President and a director of Gain Therapeutics (GANX), received a grant of 200,000 derivative shares (reported as an award) on March 24, 2026. The Form 4 lists the per-share price as $0.00 and does not report an immediate cash value. This was an equity award (not an open-market buy or sale).
Key Details
- Transaction type: Award/Grant of derivative securities (code A)
- Transaction date: 2026-03-24; Form 4 filed 2026-03-26 (filed within the typical two-business-day window)
- Amount: 200,000 underlying shares reported; price shown as $0.00 (no dollar value reported on the form)
- Vesting (footnote F1): 25% vests on March 24, 2027; remaining 75% vests in 36 equal monthly installments thereafter, subject to continuous service
- Shares owned after transaction: not specified in the filing
Context
- This is a time‑based equity award (derivative) tied to future vesting and continued service — not an immediate purchase or sale. Such grants are common as executive compensation and do not, by themselves, indicate trading intent or near-term buying/selling of stock.
Insider Transaction Report
Form 4
Mack Gene
DirectorCEO, President
Transactions
- Award
Employee Stock Option (right to buy)
[F1]2026-03-24+200,000→ 200,000 totalExercise: $1.86Exp: 2036-03-24→ Common Stock (200,000 underlying)
Footnotes (1)
- [F1]The shares underlying the option shall vest as to 25% on March 24, 2027, and the remainder shall vest in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service through each such vesting date.
Signature
/s/ Gene Mack|2026-03-26